• MJHLS Brand Logo

© 2022 MJH Life Sciences™ , NeurologyLive – Clinical Neurology News and Neurology Expert Insights. All rights reserved.

Testing for Early Diagnosis of Alzheimer’s Disease

Alireza Atri, MD, PhD, discusses the many methods of testing and forming a diagnosis for patients with Alzheimer’s disease, highlighting the recent FDA approval of aducanumab and its impact.

EP. 1: The Pathophysiology of Alzheimer’s Disease

January 25th 2022

Alireza Atri, MD, PhD, describes the pathophysiology of Alzheimer’s disease (AD).

EP. 2: Common Screening Tools for AD and Their Importance

January 25th 2022

Dr Atri lists the common screening tools used to form an AD diagnosis.

EP. 3: Biomarker Testing and its Role in an AD Diagnosis

February 1st 2022

An expert explains the role biomarker testing plays when diagnosing a patient with AD.

EP. 4: Aducanumab’s FDA Approval to Treat AD

February 1st 2022

Alireza Atri, MD, PhD, discusses aducanumab’s recent FDA approval for the treatment of AD.

EP. 5: Diagnostic Evaluation for Using Aducanumab in Patients With AD

February 8th 2022

Dr Atri explains how aducanumab plays a role in diagnostic evaluations for patients with AD.

EP. 6: Diagnostic Evaluations Continued

February 8th 2022

Dr Atri continues his discussion on aducanumab and AD diagnostic evaluations.

EP. 7: The Importance of Different Tests When Caring For Patients With AD

February 8th 2022

Alireza Atri, MD, PhD, concludes with a discussion on how different testing methods impact the care of patients with AD.